Omacetaxine mepesuccinate
- Generic Name
- Omacetaxine mepesuccinate
- Brand Names
- Synribo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39NO9
- CAS Number
- 26833-87-4
- Unique Ingredient Identifier
- 6FG8041S5B
- Background
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 200...
- Indication
Used in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
- Associated Conditions
- Refractory, accelerated phase Chronic myeloid leukemia, Refractory, chronic phase Chronic myeloid leukemia
- Associated Therapies
- -
Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase
- First Posted Date
- 2003-12-05
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00003694
- Locations
- 🇺🇸
Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States
Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00030355
- Locations
- 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00006364
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.